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Summary: We compared the inter-method differences shown by control materials and by patients' sera for the
measurement of some plasma proteins in the same pair of analytical systems. Sets of 100 to 110 samples of patients'
sera and of 18—19 control materials, including the recently available CRM 470, were assayed with up to five
automatic analytical systems, in two different experiments. About 5500 values were produced and assessed statistic-
ally. Materials (either patients' sera or control materials) were considered non-commutable (i. e. exhibiting signifi-
cantly different inter-method behaviour) when their distance from the regression line in a stated pair of methods ex-
ceeded 3 standard deviations. According to this criterion, less than 1.5% of the patients' sera, and an even lower propor-
tion of control materials were non-commutable. However, the inter-method behaviour of control materials was usually
slightly different from that of patients' sera. Some systematic inter-method difference in the measurements on patients'
sera may therefore exist, even though inter-method equivalence has been demonstrated with control materials.
Introduction
Plasma protein measurements show great variability be-
tween laboratories (1), mainly due to calibration prob-
lems (1, 2). The purpose of calibration is to ensure that
the results from patients' sera are as close as possible
to the "true" value, and that the results from different
procedures are as close as possible to each other. In
practice, calibration is performed using "materials",
mostly provided by industry; for such materials to serve
the expected purpose, they have to show inter-method
properties comparable to those of patients' sera. This
characteristic, known as commutability, was first studied
for enzyme materials (3). Occurrence of non-commuta-
bility has been reported for a variety of non-enzymatic
components (4-^6).
Here we report the results from two experiments, using
different analytical systems, and planned to assess the
commutability of a number of commercial control mate-
rials for the immunoassay of certain serum proteins. The
two experiments involved a variable number of laborato-
ries (two to three), analytical systems (four to five), se-
rum proteins (two to four), and control materials (eigh-
teen to nineteen). The second experiment also included
a certified reference material (CRM 470).
Materials and Methods
Different sets of from 100 to 110 samples of fresh patients' serum,
covering wide intervals of concentration, were used in the two ex-
periments. A total of 26 commercial control materials, either lyophi-
lized or liquid, were also used (tab. 1). The CRM 470 was obtained
by BCR, Brussels (courtesy of Beckman Analytical, Milano).
Immunoglobulins A, G and M (IgA, IgG, IgM) and transferrin
were measured in the patients' sera (in duplicate) and in the control
materials (four replicates), using five automatic systems, based on
immuno-turbidimetry (AU 560, Olympus; and Specific Plus, Kone)
or immunonephelometry (QM 300, Kallestad; BNA, Behring; and
APS 360, Beckman). Each system was operated with the reagents
and the calibrators supplied by the respective manufacturer. Be-
tween the first and the second experiment some modifications in
the operating protocol of the AU 560 system were introduced, in-
cluding modified anti-sera dilution ratios, modified sample volume
fractions, and new lots of anti-sera and calibrators.
Analytical imprecision was calculated from duplicate results on
patients' sera. Mean values from duplicate or quadruplicate mea-
surements were used for further calculations. The inter-method re-
lationship in the measurement of patients' sera with pairs of meth-
ods was assessed by means of linear regression, calculated accord-
ing to the standardized principal component model (8); the residual
standard deviation was computed as a measure of the dispersion
around the line. Results from the AU 560 system were consistently
assigned the x-axis, in order to have a common comparison basis
for the other systems.
For the assessment of commutability, y'-values were computed
from each set of x-values (patients1 sera) using the relevant regres-
sion equation; the differences [y-y'] (residuals) were devided by
their standard deviation to yield the "normalized residuals". Nor-
malized residuals were also calculated for the control materials.
Any material (patient serum or control material) showing a normal-
ized residual outside the ± 3 interval was considered non-commut-
able (9). About 5500 single analytical values were produced: none
was excluded from statistical calculations.
Results
Table 2 shows the within-run imprecision of the five
analytical systems at different protein concentration val-
ues.
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Results of the methods comparison on patients' sera are
shown in figures 1 and 2; the statistical evaluation of
the inter-methods relationships is shown in table 3.
The distribution quantities (mean, SD, and number out-
side the ± 3 interval) of the two populations of normal-
ized residuals, from patients' sera and control materials
respectively, are listed in table 4; the normalized residu-
als of the CRM 470 are listed in the table on a separate
column.
In figure 3 the inter-method behaviour of the control
materials and of the patients' ser^ are compared for
some representative pairs of methods. Two examples of
Tab. 1 Control materials used in the two experiments.
Exp.
&1I
&I I
&I1
&II
&I1
&I1
&II
&1I
&II
&II
&II
II
II
II
u
11
II
II
Material
Monitrol I
Monitrol II
Human Protein Reference Serum
Precinorm U
Precipath U
Precinorm Protein
Seronorm Human
Sernorm Protein
Bio-rad 1
. Bio-rad 2
Bio-rad 3
Bio-rad 4
Ortho Cortina
Ortho Cervinia
Decision Level 1
Decision Level 2
Decision Level 3
Kontrollagen L
Kontroll agen LP
N/T
CRM 470
Vigil PRx 1
Vigil PRx 2
Vigil PRx 3
Liquicheck 1
Liquicheck 2
Manufacturer
Baxter
Baxter
Orion
Boehringer
Boehringer
Boehringer
Nycomed
Nycomed
Biorad
Biorad
Biorad
Biorad
Ortho
Ortho
Beckman
Beckman
Beckman
Behring
Behring
Behring
BCR
Beckman
Beckman
Beckman
Biorad
Biorad
Physical state
lyophilized
lyophilized
lyophilized
lyophilized
lyophilized
liquid
lyophilized
lyophilized
lyophilized
lyophilized
lyophilized
lyophilized
lyophilized
lyophilized
liquid
liquid
liquid
lyophilized
lyophilized
liquid
lyophilized
liquid
liquid
liquid
liquid
liquid
Matrix
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
human
Specific for
serum proteins
no
no
yes
no
no
yes
no
yes
no
no
no
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
Tab. 2 Analytical (within-series) imprecision of the five systems, from duplicate results, at two
concentration levels (Lo and Hi).
Protein
IgA
IgA
IgM
IgM
Transferrin
Transferrin
IgG
IgA
IgM
IgM
Transferrin
Transferrin
IgG
IgA
IgM
Transferrin
IgM
IgM
Transferrin
IgM
Transferrin
System
AU 560
AU 560
AU 560
AU 560
AU 560
AU 560
QM300
QM300
QM300
QM300
QM300
QM300
SPECIFIC
SPECIFIC
SPECIFIC
SPECIFIC
BNA
BNA
BNA
APS 360
APS 360
Exp.
I
I
I
II
I
II
I
I
I
II
I
II
I
I
I
I
I
II
II
II
II
n
Lo
56
55
55
55
51
55
55
52
53
55
43
55
50
46
53
50
56
55
55
55
55
Hi
44
45
45
55
49
55
45
48
47
55
57
55
50
54
47
50
44
55
55
55
55
Mean (g/I]
Lo
12.2
1.95
1. 18
1.67
1.94
1.73
13.3
1.96
0.92
1.29
2.25
1.82
13.7
1.67
1.13
2.23
1.62
2.11
1.91
1.48
1.70
f
Hi
28.9
6.54
3.63
4.87
3.08
3.41
30.9
7.58
3.25
3.78
3.49
3.48
30.8
6.68
4.51
3.40
5.57
6.32
3.62
4.31
3.33
CV (%)
Lo
1.23
1.66
0.80
3.31
2.32
3.62 ·
2.83
3.26
4.30
3.90
1.85
5.60
1.56
3.35
5.24
1.34
3.29
1.62
* 3.30
•
(
 1.83
1.74
Hi
1.86
1.02
1.45
4.64
2.31
3.88
2.30
3.19
5.38
3.04
2.39
5.25
2.19
4.35
2.47
1.37
1.46
3.46
2.85
1.53
1.48
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inter-method behaviour of control materials overlapping
that of patients' sera (diagrams 3a and 3b), and two ex-
amples of inter-method behaviour of control materials
systematically different from that of patients' sera (dia-
grams 3c and 3d) are shown. Only two materials (circled
in diagram 3d) show lack of commutability, according
to the criterion chosen.
Discussion
Casual and systematic inter-method differences in the
measurement of some plasma proteins are confirmed by
our results (fig. 1 and 2, tab. 3). Whilst it seems reason-
able to speculate that matrix effects and/or molecular
heterogeneity are mainly responsible for the former, cal-
ibration problems appear to be mainly responsible for
10 20 30 40 50 60
IgG (AU 560) [g/l] IgA (AU 560) [g/l]
I
I
1
2 4 6 8 10 12 14
IgM (AU 560) [g/l]
0 1 2 3 4 5 6
Transferrin (AU 560) [g/l]
Fig. 1 Method comparison on patients' sera (from 100 to 110 assigned the y-axis. The regression lines were calculated according
samples): results from experiment I. For uniform comparison, the the standardized principal component model.
values from the AU 560 system were consistently assigned the x- ( S): QM 300
axis, and the results from the alternative analytical systems were ( +): Specific
(— X): BNA
0 2 4 6 β 10 12 14
IgM (AU 560) [g/l]
Fig. 2 Same as figure 1, results from experiment II.
( B): QM300
( +): Specific
(— X): BNA
0 1 2 3 4 5
Transferrin (AU 560) [g/l]
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the latter (slope values different from 1). As a matter of
fact, mathematical manipulation of the results, using
CRM 470-derived factors supplied by the manufactur-
ers, has been shown to substantially improve the inter-
method comparability of results in the measurement of
a number of serum proteins in a sample-group of refer-
ence individuals (10). Previous results on the effect of
the calibration procedure (1), and the expected practical
impact of the CRM 470 (2) are thereby confirmed.
In this work, by comparing the inter-method behaviour
of control materials and of sets of patients' sera over
wider concentration intervals, we have assessed the in-
trinsic characteristic of the "materials" commonly re-
ferred to as commutability. According to a previously
suggested criterion (9), most of the materials showed
commutable, such a low rate of non-commutability
events (< 1.5%) being partly due to'the large variability
of the inter-method differences exhibited by patients'
sera (5). However (tab. 4), the normalized residuals from
patients' sera were distributed as theoretically expected
(mean = 0; standard deviation = 1), whilst those from
the control materials were distributed within narrower
limits (standard deviation < 1) but frequently not
Tab. 3 Linear regression analysis (standardized principal compo-
nent) of the results from systems comparison, in the assay of pa-
tients' sera. Results from the AU 560 system were consistently
assigned the x-axis, those from the compared system the y-axis.
Residual standard deviations (Syx) are shown as a measure of the
dispersion around the line.
Protein
IgG
IgG
IgA
IgA
IgM
IgM
IgM
IgM
IgM
IgM
Transferrin
Transferrin
Transferrin
Transferrin
Transferrin
Compared
system (y-axis)
. QM 300
SPECIFIC
QM300
SPECIFIC
QM300
SPECIFIC
BNA
QM300
BNA
APS 360
QM300
SPECIFIC
QM300
BNA
APS 360
Exp.
I
I
I
I
I
I
I
II
II
II
I
I
II
II
II
n
100
100
100
100
100
100
100
110
110
110
100
100
110
110
110
Syx)
(g/1)
1.22
2.14
0.53
0.61
0.36
0.52
0.42
0.36
0.56
0.30
0.18
0.27
0.20
0.15
0.16
Interval of
x-values (g/1)
4.33 - 44.21
4.33 - 44.21
0.68 -s- 12.28
0.68 - 12.28
0.40- 8.69
0.40 - 8.69
0.40+ 8.69
0.32- 8.56
0.32- 8.56
0.32- 8.56
0.93 - 4.29
0.93- 4.29
0.50- 4.44
0.50- 4.44
0.50- 4.44
y-Intercept
(g/D
+ 0.48
+ 0.99
-0.68
-0.58
-0.28
-0.42
-0.35
-0.18
-0.24
-0.11
+ 0.26
+ 0.26
+ 0.04
+ 0.08
+ 0.02
Slope ±S.E.
1.06 ±0.012
1.08 ± 0.022
1.33 ±0.020
1.23 ± 0.023
1.00 ± 0.024
1.38 ± 0.034
1.62 ± 0.028
0.83 ±0.018
1.36 ± 0.028
0.92 ± 0.015
1.09 ±0.025
1.02 ±0.039
1.02 ±0.019
1. 04 ±0.014
0.97 ±0.015
Tab. 4 Assessment of commutability: distribution quantities of
the two populations of normalized residuals from patients' sera (n
from 100 to 110) and control materials (n from 17 to 19). The
normalized residuals from the CRM 470 are tabulated in a separate
column for comparison. Results from each alternative system were
compared with the AU 560 system.
Protein
IgG
IgG
IgA
IgA
IgM
IgM
IgM
IgM
IgM
IgM
Transferrin
Transferrin
Transferrin
Transferrin
Transferrin
System
compared
QM300
SPECIFIC
QM300
SPECIFIC
QM300
QM300
SPECIFIC
BNA
BNA
APS 360
QM300
QM300
SPECIFIC
BNA
APS 360
Exp. Normalized residuals from
Patients' sera
I
I
I
I
I
II
I
I
II
II
I
II
I
II
II
m
0.00
0.00
0.00
0.00
0.01
-0.01
-0.01
0.01
0.00
0.00
0.01
-0.02
-0.02
0.04
0.00
SD
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1. 00
1.00
1.00
1.00
1.00
Control materials
outside m
±3
0
0
2
1
3
2
1
2
2
1
1
3
1
1
2
-0.10
-0.12
0.10
0.30
-0.25
0.63
-0.54
0.58
1.16
0.82
-2.02
1.80
-1.60
0.90
0.68
SD
0.28
0.54
0.52
0.26
0.44
0.35
0.55
0.52
0.47
0.56
0.55
0.98
0.50
1.44
1.00
CRM
Air\
Line
*f /U
outside
± 3
0
0
0
0
0
0
0
0
0
0
0
3
0 '3 ·<
1
_
-
_
-
0.83
__.
0.74
0.84
_
2.12
1.03
1.50
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
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4 6 8 10 12 14 16 18
IgG (AU 560) [g/l]
2 3 4 5
IgA (AU 560) [g/l]
1 2 3 4 5 6
IgM (AU 560) [g/l]
Fig. 3 Representative examples of the inter-method behaviour of
control materials (crosses) compared with patients' sera (regression
lines, standardized principal component model). Diagrams a, b, c,
and d, correspond, respectively, to lines 1, 3, 9, and 14 of table 4.
2 4 6 8
Traneferrln (AU 560) [g/l]
In diagrams a and b the points distribute on the two sides of the
line, in diagram c and d they distribute mainly or exclusively on
one side of the line. In diagram d two points outside the line by
more than 3 residual standard deviations are circled.
around 0. These data mean that the sample-group of mate-
rials shows inter-method changes more homogeneous
than the sample-group of patients' sera. Nevertheless, and
in spite of low frequency of non-commutability events,
the two groups differ from each other in their inter-method
behaviour: the CRM is closer to the control materials than
to patients' sera. Similar behaviour was shown by the con-
trol materials for cholesterol measurement (11).
These findings suggest that, in most cases, the inter-
method differences measured with either a control mate-
rial or a fresh serum sample are expected to show statis-
tically significant agreement. Nevertheless, when many
of the tested materials (including the CRM 470) are used
to directly check for (control), or to pursue (calibration)
consistency in measurements by different methods,
some residual differences may still exist when these
methods are applied to fresh sera.
Therefore, transfer of accuracy and accurate inter-method
comparison are best performed with protocols that also in-
clude direct method comparison on a large series of split
serum samples (12, 13). Alternatively, the commutability
of the materials should be verified. Although some of the
differences observed between experiments I and II may be
due to differences in the sets of patients' sera, it seems that
both the inter-method differences and the degree of com-
mutability of the control materials are sensitive to varia-
tions in the assay protocol. This further suggests the need
for a frequent check of such properties.
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